Pfizer’s Refocus May Bring Clarity for Lpath
By Marie Powers
Wednesday, October 9, 2013
Lpath Inc. moved quickly to digest the disappointment that partner Pfizer Inc. plans to divest “a number of” its ophthalmology R&D assets, including its exclusive option for a global license to develop and commercialize Lpath’s wet age-related macular degeneration (AMD) candidate Isonep.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.